Exploration of Practical Biomarkers for Systemic Drug Therapy for Hepatocellular Carcinoma
Preprint
- 17 July 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
A number of agents, including immune checkpoint inhibitors, have become available for the treatment of hepatocellular carcinoma (HCC). However, the objective response rate of these drugs is currently only 30% to 40%, with a high incidence of side effects. There are also no prac-tical biomarkers to predict their therapeutic effects. Most of the systemic therapies for HCC are performed in general hospitals without research facilities. Such hospitals can perform imaging tests, like CT and MRI, as well as pathological diagnosis using tumor tissue sampling and im-munohistochemical staining. However, analyzing tumor genomic or transcriptomic profiles is difficult because of limitations in facilities, personnel, and cost. Therefore, in this review, we provide an overview of the wide range of research that has been conducted on HCC biomarkers from blood, tissue, or imaging information that can be used practically in general hospitals for predicting the therapeutic effect of systemic therapies before treatment begins. For general hos-pitals that treat HCC patients, we recommend conducting treatment after assessing the state within the tumor tissue as much as possible by collecting blood and tissue samples and per-forming pre- treatment MRI image evaluations.Keywords
All Related Versions
This publication has 102 references indexed in Scilit:
- The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinomaHepatology, 2023
- Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective studyHepatology International, 2022
- Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinomaHepatology, 2022
- Epidemiology of Hepatocellular CarcinomaHepatology, 2020
- Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma modelsCancer Medicine, 2018
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of SorafenibJAMA, 2014
- Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinomaHepatology, 2014
- Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology, 2013
- MicroRNAs: New Tools for Diagnosis, Prognosis, and Therapy in Hepatocellular Carcinoma?Hepatology, 2013
- FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinomaHepatology, 2012